Moreover we analysed the anti-apoptotic factor Bcl-2 and we observed the MPTP significantly reduced the expression of Bcl-2; instead TO901317 treatment significantly restored Bcl-2 expression (Fig 6F and 6F1), confirming the results obtained in in vivo model of PD. This evidence concerns the gene BCL2 and Parkinson disease.